Search results for "frovatriptan"

showing 5 items of 5 documents

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, …

2012

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were…

AdultTime FactorsOriginalMigraine DisordersPopulationAlmotriptanClinical NeurologyCarbazolesSubgroup analysisSeverity of Illness IndexAdult; Carbazoles; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Italy; Menstruation Disturbances; Middle Aged; Migraine Disorders; Proportional Hazards Models; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors; Treatment Outcome; TryptaminesDisability EvaluationDouble-Blind MethodAlmotriptanSeverity of illnessMedicineHumanseducationMigraine Menstrually related migraine Frovatriptan AlmotriptanMenstrually related migraineMenstruation DisturbancesMigraineMenstrually related migraineProportional Hazards Modelseducation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTryptaminesSerotonin Receptor Agonistsfrovatriptan; migraine; menstrually related migraine; almotriptanAnesthesiology and Pain MedicineTreatment OutcomeMigraineItalyAnesthesiaFemaleNeurology (clinical)businessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Suggested randomized, controlled trial for frovatriptan: a reply

2011

Dear Sir, We read with interest the comments of Dr. Tfelt-Hansen [1] regarding our three recently published randomized controlled trials comparing patients’ preference (primary endpoint) and efficacy (secondary endpoints) of frovatriptan 2.5 mg versus zolmitriptan 2.5 mg [2], rizatriptan 10 mg [3] and almotriptan 12.5 mg [4], and the meta-analysis of pooled individual data from the three studies [5]. In all studies frovatriptan showed similar preference and short-term efficacy outcomes (pain relief and pain-free episodes at 2 h) with respect to the other three triptans. The questions put by Dr. Tfelt-Hansen sound appropriate. Doubts are raised on the usefulness of head-to-head preference tr…

medicine.medical_specialtybusiness.industryClinical NeurologyZolmitriptanGeneral MedicineTriptansmedicine.diseaseRizatriptanEfficacySumatriptanAnesthesiology and Pain MedicineMigraineAlmotriptanmedicinefrovatriptan controlled trial migraineNeurology (clinical)Intensive care medicinebusinessFrovatriptanLetter to the Editormedicine.drugThe Journal of Headache and Pain
researchProduct

A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

2011

The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints w…

AdultMaleAdolescentOriginalMigraine with AuraPopulationAlmotriptanCarbazolesClinical NeurologyMigraine; almotriptan; FrovatriptanYoung Adultalmotriptan; frovatriptan; migraine; patient preferenceDouble-Blind MethodAlmotriptanmedicineHumansMigraine Frovatriptan Almotriptan Patient preferencePatient preferenceeducationMigraineAgededucation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyRizatriptanTryptaminesMigraine with auraSerotonin Receptor AgonistsalmotriptanTreatment OutcomeAnesthesiology and Pain MedicineItalyMigraineTolerabilityAnesthesiaAcute DiseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptombusinessFrovatriptanFrovatriptanmedicine.drug
researchProduct

When to use frovatriptan in migraine? A reply

2011

Dear Sir, We read with interest the comments of Dr. Tfelt-Hansen [1] on the two recently published randomized controlled trials comparing patients’ preference (primary end-point) and efficacy (secondary end-points) of frovatriptan with respect to rizatriptan [2] and almotriptan [3]. In both studies, frovatriptan showed similar preference and short-term efficacy outcomes (pain relief and pain free episodes at 2 h) with respect to the other two triptans. The principal concern of Dr. Tfelt-Hansen was the very early use of frovatriptan in these studies, making their results hardly comparable with those of previous randomized controlled trials [4–6], where patients waited until the headache was …

medicine.medical_specialtybusiness.industryClinical NeurologyGeneral MedicineTriptansPlacebomedicine.diseaseRizatriptanlaw.inventionSumatriptanAnesthesiology and Pain MedicineRandomized controlled trialMigrainelawAlmotriptanInternal medicineMedicineMigraine Frovatriptan Almotriptan Patient preferenceNeurology (clinical)businessPsychiatryFrovatriptanLetter to the Editormedicine.drug
researchProduct

Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study

2013

Results 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2and 4-hrs was 36% and 53% for frovatriptan and 41% and 50% for almotriptan (p=NS between treatments). Rate of pain free at 2and 4-hrs was 19% and 47% with frovatriptan and 29% and 54% for almotriptan (p=NS). At 24-hrs, 62% of frovatriptanand 67% of almotriptan-treated patients had pain relief, while 60% vs. 67% were pain free (p=NS). Recurrence at 24-hrs was significantly (p<0.05) lower with f…

medicine.medical_specialtyeducation.field_of_studyTraditional medicinebusiness.industrymedia_common.quotation_subjectPopulationPain reliefClinical NeurologySubgroup analysisGeneral Medicinemedicine.diseaseAnesthesiology and Pain MedicineMigraineInternal medicineAlmotriptanFemale patientPoster PresentationmedicineNeurology (clinical)FrovatriptaneducationbusinessMenstrual cyclemedicine.drugmedia_commonThe Journal of Headache and Pain
researchProduct